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■ CLINICAL COMMENTARY
hs-CRP may be useful as a risk marker 
in some moderately high-risk patients
Elevated hs-CRP is not a standard cardiovascu-
lar risk factor, but may be useful for patients
with Framingham Risk scores of 10% to 20%.
The updated National Cholesterol Education
Panel Adult Treatment Panel III guidelines list
elevated hs-CRP (>3 mg/L) as an influencing
factor in deciding whether to use an LDL-lower-
ing drug for moderately high-risk patients with
LDL-cholesterol values <130 mg/dL.13 However,
no prospective studies prove that elevated hs-
CRP should guide therapy. The JUPITER trial is
a prospective, placebo-controlled trial evaluat-
ing cardiovascular events with statin therapy in
primary prevention patients with LDL values
<130 mg/dL and hs-CRP values >2 mg/L.14
When this study is completed, the definitive
clinical utility of hs-CRP will be known. Until
then, hs-CRP is a risk marker that may be use-
ful for some moderately high-risk patients.
Joseph Saseen, PharmD, FCCP, BCPS, University
of Colorado Health Sciences Center, Denver
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How should we follow up 
a positive screen for anemia 
in a 1-year old?
■ EVIDENCE-BASED ANSWER
Healthy infants who test positive for anemia on
routine screening at 1 year of age are most likely
iron-deficient and may be treated empirically with
a trial of iron therapy (3–6 mg of elemental
iron/kg/d). Documentation of response to iron
confirms the diagnosis of iron-deficiency (strength
of recommendation [SOR]: B; evidence from ran-
domized controlled trials with some conflicting
results; lack of evidence for long-term benefits/
harms of screening strategies). 
In these cases, further testing with a complete
blood count, mean corpuscular volume, red cell
distribution width (RDW), serum ferritin concen-
tration, as well as hemoglobinopathy screening
when appropriate,  may be effective in determin-
ing the cause of anemia (SOR: C, expert opinion).  
■ EVIDENCE SUMMARY
A prospective study of 1128 children identified as
anemic with a screening hemoglobin level showed
that subsequent testing—which included mean cor-
puscular volume, protoporphyrin, transferrin, and
ferritin measurements—did not reliably distinguish
potential responders from nonresponders to a 3-
month trial of empiric iron therapy.1 In fact, more
than half of the responders would have been missed
if treatment had been restricted to infants with
abnormal mean corpuscular volume or iron studies. 
Because of the simplicity, low cost, and relative
safety of iron therapy for infants, this trial sug-
gests that a therapeutic trial of iron be given first,
reserving further work-up for the small number of
infants that still have unexplained hemoglobin
concentrations of <11.0 g/dL after a therapeutic
trial. Similar results were found in a prospective
controlled treatment trial among Alaskan Native
children2 as well as a trial of empiric iron therapy
among infants with anemia.3
It is not clear whether hs-CRP is a
causative marker for atherosclerosis
or simply a proxy marker
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Another prospective study of 970 healthy
infants identified 62 infants with a heel-stick capil-
lary hematocrit of <33%. Of these, 31 had repeat
hematocrit values of <33% as confirmed by subse-
quent heel-stick complete blood count measure-
ment. Twenty of these anemic infants (65%) 
completed the study protocol, which included a 
1-month trial of iron, a follow-up complete blood
count, and hemoglobin electrophoresis for those
infants with persistent microcytosis or positive
sickle preparation (performed at initial screening
for all African American infants). Six infants (30%)
had an increase in hemoglobin concentration of 1.0
g/dL or more and were presumed to be iron-defi-
cient; they went on to receive an additional 2
months of iron therapy. Two of these were found to
have co-existing alpha-thalassemia. Of the remain-
der, 11 (55%) were determined to have a low-nor-
mal hematocrit (mean=31.5 ± 0.9), 1 had alpha
thalassemia alone, 1 had coexisting alpha-tha-
lassemia and hemoglobin AS, and 1 had hemoglo-
bin SC. Review of data showed that abnormal diag-
noses (iron deficiency, thalassemia, and sickle cell
trait or disease) were found in 9 of 11 infants with
high RDW and in none of the 9 with normal RDW.
The authors concluded that RDW alone appears to
be predictive of identifiable causes of anemia when
used to screen healthy 12-month-old babies.4
A recent Cochrane review suggests there is a
clinically significant benefit for the treatment of
iron-deficiency anemia; however, there is a need for
further randomized controlled trials with long-term
follow-up.5 A randomized controlled trial of iron
supplementation vs placebo in 278 infants testing
positive for iron-deficiency anemia demonstrated
that once daily, moderate-dose ferrous sulfate
(FeSO4) therapy (3 mg/kg/d of elemental iron)
given to fasting 1-year-old infants results in no
more gastrointestinal side effects than placebo
therapy.6 Another study demonstrated that iron sul-
fate drops (40 mg elemental iron divided 3 times a
day) or a single daily dose of microencapsulated
ferrous fumarate sprinkles (80 mg elemental iron)
plus ascorbic acid resulted in a similar rate of suc-
cessful treatment of anemia without side effects.7
In a retrospective cohort study8 of 1358 inner-
city children aged 9 to 36 months who underwent
screening, 343 (25%) had anemia (Hgb <11 g/dL);
of these, 239 (72%) were prescribed iron and 95
(28%) were not. Responders were defined as
those with a hemoglobin value of greater than 11
g/dL or an increase of 1 g/dL documented within
6 months of the initial screening visit. Follow-up
rates for both groups were low (~50%), but of
those prescribed iron, 107 of 150 (71%) respond-
ed to treatment compared with 27 of 48 (68%) of
those who did not receive iron. Since similar
response rates were seen among infants who did
and infants who did not receive iron therapy, prov-
ing the benefit of routine screening followed by a
trial of iron may be problematic in populations
with higher rates of anemia, low follow-up rates,
and high spontaneous resolution rates.
■ RECOMMENDATIONS FROM OTHERS
The United States Preventive Services Task
Force,9 American Academy of Family Physicians,10
and American Academy of Pediatrics11 recom-
mend screening infants for iron-deficiency anemia
but do not address appropriate follow-up for posi-
tive screens.
The Centers for Disease Control and
Prevention (CDC) guidelines recommend perform-
ing a confirmatory hemoglobin and hematocrit
after a positive anemia screening. If anemia is
confirmed and the child is not ill, then treat with
iron replacement (3 mg elemental iron/kg/daily)
for 4 weeks followed by a repeat test. An increase
in hemoglobin concentration ≥1 g/dL or in hemat-
ocrit ≥3% confirms the diagnosis of iron-deficien-
cy anemia. If iron-deficiency anemia is confirmed,
they recommend continuing iron therapy for 
2 more months (3 months total treatment), and
rechecking hemoglobin or hematocrit 6 months
after successful treatment is completed.
Nonresponders, despite compliance with the iron
Further work-up should be reserved
for those infants having unexplained
hemoglobin concentrations <11.0 g/dL
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supplementation regimen and the absence of
acute illness, should undergo further evaluation
including mean corpuscular volume, RDW, and
serum ferritin concentration.12
Stephen Scott, MD, Department of Family and Community
Medicine, Houston, Tex; Marlene Porter, MLS, 
Medical College of Ohio, Toledo
■ CLINICAL COMMENTARY
Treating anemia without testing for the
cause is the approach of most FPs
For infants 9 months to 1 year of age, there is
no consensus regarding appropriate follow-up
of positive screens for anemia. It is known that
most of them have iron deficiency anemia and
empiric treatment with iron supplements have
been studied in several prospective trials.
It is also unclear which red cell indices should
be tested for diagnosing the different types of
anemia. One study found RDW testing alone
could predict the cause of anemia. Based on my
clinical experience with inner-city Hispanic
babies, CDC guidelines seem to include appro-
priate follow-up. A Cochrane review suggests
the need for further randomized controlled tri-
als with long-term follow-up. There is evidence
that treating anemia without initial testing for
the cause is the approach of choice of most
physicians, and there is some evidence that fur-
ther testing may delay or result in nontreat-
ment of infants who would have benefited from
iron therapy.
Yasmeen Quadri, MD, Baylor College of Medicine,
Houston, Tex
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■ CORRECTION
The authors of an article in the October 2004 issue of The
Journal of Family Practice have requested a correction to
the article’s title and Practice Recommendation.  The new
title and recommendation (below) omit an earlier mention
of breast cancer.
[Title]
Raloxifene reduces risk of vertebral fractures in post-
menopausal women regardless of prior hormone therapy
[Practice Recommendation]
Consider prescribing raloxifene 60 mg/d for postmenopausal
women, regardless of whether they have used hormone ther-
apy, to reduce the incidence of vertebral fractures
The authors wish to note that raloxifene is not approved in
the United States for use in reducing the incidence or risk
of breast cancer.
